Testing, Pathogen Inactivation Or Both? Experts Predict Blood Safety’s Future
This article was originally published in The Gray Sheet
Pathogen inactivation likely will supersede testing as the primary method of preventing the spread of pathogens through blood transfusions in the developing world, according to participants at a June 4 transfusion safety symposium at NIH
You may also be interested in...
Blood pathogen reduction technology may benefit only non-immunosuppressed patients if FDA determines that the inactivation agents pose a toxicological risk
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.